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Introduction
The combination of incarceration and chronic ill-
ness can be a potent formula for mental health
disorders. Even without the burden of a chronic
infectious disease, inmates have a high preva-
lence of mental illness. The Bureau of Justice
reports that in the year 2000, 13% of all state
prisoners received psychotherapy or counseling
and 10% received psychotropic medications.1
In the free world, HIV and chronic viral hepatitis
are commonly accompanied by significant men-
tal health problems. A recent community survey
of psychiatric and substance abuse disorders
among people actively treated for HIV infection
found that 36% had a major depressive disorder,
15% a generalized anxiety disorder and 10%
panic attacks.2 Not surprisingly, drug abusing
HIV-infected individuals were three times more
likely to have a psychiatric disorder. These rates
are far higher than those seen in samples of non-
HIV-infected individuals. In addition, the same
study found that almost one-third of those with
HIV infection were taking psychotropic medica-
tions and one-fourth were receiving specialty
mental health care.
Although statistics concerning the prevalence of
mental illness among HIV-infected inmates vary
depending on the setting, the dual impact of
chronic illness and incarceration makes it com-
monplace for correctional health care providers
to encounter inmates with major mental disor-
ders.
Although most correctional systems maintain
screening and treatment programs for both HIV
infection and mental illness, numerous disincen-
tives to being diagnosed with HIV infection or a
psychiatric disorder make it likely that many
patients who could benefit from treatment are not
identified. Those recently diagnosed with HIV
infection, those whose health is deteriorating,
those serving a first term, and older prisoners are
also more likely to have mental health problems. 
The potential benefits of mental health treatment
for inmates are numerous. Treatment can
decrease the likelihood of self-destructive behav-
ior, adherence to complex medical regimens
such as HAART and interferon/ribavirin can be
improved, and those receiving mental health
treatment generally have fewer rule violations
and therefore have shorter sentences. When
inmates with serious psychiatric disorders are not
reated they can deteriorate mentally and physi-
cally, leading to the need for more intensive and
more expensive care.
Common Mental Health Problems
Inmates with HIV infection and other chronic ill-
nesses commonly suffer from depression and
anxiety.3 The high prevalence of alcohol and/or
drug addiction among inmates further increases
the likelihood of inmates having at least one psy-
chiatric disorder.2,3 Even without meeting the
trict criteria for diagnosis of a psychiatric disor-
der, HIV-infected inmates experience a higher
degree of distress, discouragement, and demor-
alization than their uninfected counterparts.
Inmates who have spent time in segregated
housing units (SHU) (also referred to as "the
hole" or "the box") can also suffer from significant
mental health problems associated with these
"prisons within prisons".4
Depression can be manifested by an extended
period of low mood or lack of interest in activities.
In addition, depressed inmates can exhibit poor
concentration, disturbances of appetite and
sleep, agitation, irritability, hopelessness, social
isolation, and ruminations about death and/or
suicide. Depression among the chronically ill can
present as a somatic syndrome without objective
findings, leading health care providers to futilely
pursue an extensive and costly medical workup. 
Many inmates exhibit anger and hostility, making
it difficult to work with them. These traits may be
symptoms of an underlying psychiatric disorder
such as a personality disorder, depression, or
even bipolar (manic-depressive) disorder.
Anxiety syndromes are characterized by a
heightened and often-exaggerated sense of
dread, fear, or worry. These "cognitive" symp-
toms are often accompanied by a panoply of
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symptoms such as palpitations, shortness of
breath, a choking sensation, diaphoresis,
nausea, urinary urgency, tachycardia, and
dizziness. The severity of symptoms can
vary markedly. While some patients may
have panic attacks lasting from a minute to
hours, others may have only heightened
worry or fear about a particular situation.
Anxiety syndromes often have a significant
physical component that can be mistaken for
organic illness.
Inmates may suffer post-traumatic symp-
toms that include disturbing intrusive
thoughts, frantic efforts to avoid them, night-
mares, loss of interest in activities, memory
lapses, autonomic changes, and sleep dis-
turbances. Clinicians should pay special
attention to inmates who are in solitary con-
finement housing units. Recent studies have
shown that inmates can suffer a number of
psychological symptoms associated with
this type of housing.4 It was recently esti-
mated that more than 20,000 inmates were
in these types of units in the U.S.4 One com-
mentary noted that "[there] are few if any
forms of imprisonment that appear to pro-
duce so much psychological trauma and in
which so many symptoms of psychopatholo-
gy are manifested."4 Physical symptoms suf-
fered by SHU inmates may include
headaches, lethargy, heart palpitations,
dizziness, sleep disturbances, and diaphore-
sis. Thus, clinicians may be faced with dis-
criminating between symptoms of any num-
ber of HIV/hepatitis-related syndromes or
simply the mental effects of prolonged
isolation.
Lipodystrophy
Lipodystrophy (LD) represents an important
problem for HIV-infected patients receiving
highly active antiretroviral therapy (HAART).
Body changes may stigmatize patients, pro-
ducing erosion of self-image and self-
esteem, problems in social and sexual rela-
tions, and anxiety and depression. For many
patients, the benefit of survival outweighs
the limitations produced by lipodystrophy,
but others may become depressed and lose
interest in complying with complex antiretro-
viral regimens, eventually leading them to
discontinue control of their HIV infection.
Blanch, et al., performed an observational
study of the impact of LD on the quality of life
(QoL) of clinically stable outpatients taking
HAART for more than 1 year.5 QoL was
measured by the Profil der Lebensqualität
Chronischkranker (PLC), and LD was
defined by clinical criteria.
Fifty-six percent of 150 patients interviewed
fulfilled criteria for LD. Although LD was not
found to influence overall QoL in all patients,
homosexuals, the unemployed, and those
patients currently undergoing psychiatric
treatment demonstrated greater impairment
on some of the QoL subscales related to
psychological well-being if they suffered
from LD. The authors concluded that the
impact of HIV-related LD on QoL depends
on certain patient characteristics, rather than
solely on the presence of LD itself. 
Neuropsychological Issues in Patients
with Chronic Hepatitis
The prevalence of HCV infection among
inmates has been reported between 17 and
18 percent.6 Neuropsychological impair-
ment has been well documented in those
with cirrhosis and end-stage liver disease.
This impairment has been attributed to tox-
ins accumulating in the blood that are not
effectively cleared by the cirrhotic liver. 
The neuropsychological manifestations of
subcortical deficits usually include slowed
speed when processing information,
reduced word fluency, psychomotor slowing,
and impaired learning in the presence of
good recall of previously learned information
and intact recognition memory. Psychomotor
slowing, especially in combination with
impaired attention and concentration, can
result in prolonged periods of time needed to
complete even routine tasks. Verbal skills,
uch as vocabulary and naming, and basic
visuospatial and visuoconstructional abilities
are relatively unaffected. Patients with these
types of neurocognitive problems may fail to
remember (or remember incorrectly) physi-
cians' recommendations. They may experi-
ence difficulty performing their household
and job duties as efficiently and/or as accu-
rately as they are accustomed to. As a result
of these difficulties, patients can experience
frustration and mood problems, such as
depression and anxiety. 
Hilsabeck, et al., studied cognitive function-
ing in patients with chronic liver disease.7
Sixty-six patients with chronic HCV and 14
patients with other chronic liver diseases
were administered a brief battery of neu-
ropsychological tests assessing attention,
visuoconstructional ability, learning, memo-
ry, and psychomotor speed. 
Impaired performances were found in up to
50% of noncirrhotic patients, depending on
the neuropsychological function tested. In
this study, there was a significant relation-
ship between fibrosis stage and test perfor-
mance, with greater fibrosis associated with
poorer performance. Maintaining attention
and concentration for several minutes while
performing accurately was the most difficult
task for noncirrhotic patients. These findings
suggest that progressive hepatic injury may
result in cognitive problems even before the
development of cirrhosis. 
Patients with chronic HCV frequently report
fatigue, lassitude, depression, and a per-
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Table 1. Risk and Protective Factors for Suicidal Assessment
and Intervention*
Risk Factors
Historical
1. Lack of significant relationships (never married, sep-
arated, divorced)
2. Poor work history or chronic unemployment
3. Childhood abuse
4. History of violence
5. Mental disorder associated with suicidal behavior
6. History of head trauma
7. Prior suicidal behavior
8. Prior mental health treatment
9. Rigid thinking
10. Distorted thinking
11. Irrational beliefs
Psychosocial-Environmental
1. Major life stressors (re-incarceration, first incarcera-
tion, recent diagnosis of HIV, physical assault)
2. Any significant loss
3. Breakdown of social support
4. Social isolation (e.g. time in the "hole")
Clinical
1. Specific behaviors associated with suicidal behavior
(e.g. giving away belongings; saying goodbye to
friends; verbalizing thoughts of death or suicide)
2. Acute change in mental status
3. Changes in behavior
4. Mood changes
5. Changes in attitude (e.g. sudden fatalism in face of
declining T-cell count)
6. Lack of compliance
Protective Factors
1. Married or in a signifi-
cant relationship
2. Employed or involved
in a structured program
(school, treatment, etc.)
3. Intact support system
4. Having children under
the age of 18
5. Constructive use of
leisure time
6. General purpose for
living
7. Involved in mental
health treatment
8. Effective problem-
solving skills
* Sanchez HG. Risk Factor Model for Suicide Assessment and Treatment. Professional Psychology:
Research and Practice 2001;32(4):351-358.
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Dear Correctional Colleagues:
At the dawn of the last decade, there was only one FDA-approved medication for the treatme t
of HIV infection. The benefits of monotherapy with AZT were temporary at best, and the life
expectancy for patients with CD-4 counts of <50 was less than 1 1/2 years. By 1996, howev-
er, antiretroviral combinations that included protease inhibitors led to a dramatic decline in the
number of HIV-associated deaths in the United States. At the California Medical Facility in the
California Department of Corrections, there were half as many HIV-related deaths in 1996
compared to 1995, an experience repeated in jails and prisons throughout the country. There
are now 16 different FDA-approved agents available for the treatment of HIV, providing an
opportunity for prolonged, productive lives for many of those infected with HIV.
As deaths due to HIV disease declined, those attributable to the sequela of chronic HCV
increased. Now, recent advances in the treatment of chronic HCV raise hope for improvement
in liver histology, delayed progression to end-stage liver disease, and perhaps, in some cases,
actual cure from HCV.  
Not everyone has benefited from the tremendous advances in HIV and HCV treatment wit-
nessed over the past 10 years. Successful treatment outcomes demand rigorous adherence
to therapies that can cause uncomfortable and sometimes life-threatening side effects. Strict
adherence is difficult for even highly motivated, well-educated, mentally healthy individuals.
The prevalence of mental illness among the currently and formerly incarcerated is strikingly
high. Those of us working in correctional public health see firsthand how the co-morbidity of
mental illness can negatively impact on the successful treatment of HIV and chronic viral
hepatitis. 
In this issue of HEPP Report, Dr. Robert Canning provides an excellent review of the chal-
lenges facing correctional public health clinicians who treat those with mental illness and other
disorders affecting cognition. Dr. Eric Avery reflects on his personal experiences as a psychi-
atrist treating inmates in the Texas Department of Criminal Justice. And our "Ask the Expert"
section features Dr. Karl Brown from Rikers Island Jail discussing a challenging case of a bipo-
lar inmate co-infected with HIV and HCV provided by Dr. Frederick Altice of Yale University's
AIDS program.
At the conclusion of this issue, readers should have a better understanding of typical mental
disorders encountered by clinicians in the correctional setting, be aware of some useful
screening methods for the presence of mental and cognitive disorders, and be familiar with
some of the complexities of treating patients with coexisting HIV, HCV, and mental illnesses.
Joseph Bick, M.D.
Co-Chief Editor
Letter from the Editor
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ceived inability to function effectively. Studies
have shown that patients exhibit low QoL
scores that are independent of disease sever-
ity. A study by Forton, et al., evaluated
whether HCV infection has a direct effect on
the central nervous system, resulting in cog-
nitive abnormalities.8 Twenty-seven hepatitis
C viremic patients with biopsy-proven mild
hepatitis and 16 patients with cleared HCV
were tested with a computer-based cognitive
assessment battery and also completed
depression, fatigue, and QoL questionnaires.
Patients with significant fibrosis or cirrhosis
were excluded from the study, thereby exclud-
ing minimal hepatic encephalopathy as the
cause of the abnormalities. 
The authors report that HCV viremic patients
were found to be impaired on more cognitive
tasks than the HCV-cleared group. As for
affective scores, the HCV-infected group
scored worse on the Hospital Anxiety and
Depression Scales. Analysis revealed impair-
ments in power of concentration and speed of
working memory, independent of a history of
intravenous drug use, depression, fatigue, or
hepatitis symptom severity. 
The authors suggest this data supports the
clinical impression and assertions of many
HCV-infected patients that they are cognitive-
ly impaired ("brain fog"). The mechanism(s)
underlying these findings remains to be
defined. 
Kramer, et al., studied the impact of HCV
infection on cognitive brain function.9 Fifty-
eight non-cirrhotic patients with chronic HCV
infection were studied by P300 event-related
potentials (an objective measure of cognitive
processing recorded through an array of scalp
electrodes) and by the SF-36 questionnaire
for assessment of health-related QoL.
Findings were compared to 58 matched
healthy subjects.
Cognitive processing was found to be
impaired in HCV patients as compared to
healthy subjects. Similarly, P300 amplitude
was reduced in patients with HCV infection.
Health-related quality of life was significantly
reduced in patients with HCV infection but in
this study there was no clear correlation
between neurophysiological function and
health-related QoL or activity of hepatitis. 
The use of a standardized test to evaluate
depression in those undergoing treatment for
HCV was discussed at the American
Association for the Study of Liver Diseases
(AASLD) meeting in Boston in Nov. 2002.10
The development of depression while receiv-
ing IFN/RBV is one of the factors contributing
to poor adherence, early discontinuation, and
lower sustained viral response rates. In addi-
tion, treatment-related depression adversely
affects patient QoL. To facilitate the diagnosis
of depression and suicidal ideation in those
begun on IFN/RBV, patients were adminis-
tered an automated version of the Beck
Depression Index (BDI) utilizing the Point of
View (POV) 2000 hand-held survey unit. 
The BDI was given prior to therapy and
repeated within the first three months of treat-
ment and 448 patients treated with combina-
tion IFN/RBV were evaluated. Prior to thera-
py, all patients were classified by BDI as hav-
ing minimal depression.
Follow-up BDI revealed that 65% were
unchanged from baseline, 18% developed
mild depression, 9% developed moderate
depression, and 7% developed severe
depression. One percent responded that they
would kill themselves if they had the chance.
Anti-depressive therapy was initiated for all
patients who reported moderate depression
or greater.
All patients with moderate depression or less
were continued on therapy, unless suicidal
ideation was present. Twenty-two out of 30
patients with severe depression completed
therapy. Therapy was stopped for those
patients who considered suicide. Of note,
standard physician questioning did not reveal
suicide ideation in any of the 17 patients with
suicidal ideation.
The presenter concluded that the POV 2000
BDI is useful, and appears to be more sensi-
tive than standard physician interviews in
determining the presence and degree of
depression. Use of this instrument may allow
for earlier detection of depression and earlier
intervention, which may lead to greater
patient adherence to therapy. Interestingly,
many patients considering suicide did not
report severe depression.
Of Special Concern: Suicide
Suicidal behavior should always be a concern
when dealing with the chronically ill and the
incarcerated. Rates of suicide among HIV-
infected individuals are higher than among
other chronically ill populations, and HIV-
infected inmates demand careful attention. A
valuable model for dealing with suicidal think-
ing and behavior is to be aware of the risk and
protective factors affecting suicidal thinking
and behavior.11
Both risk and protective factors for suicidal
thinking and behavior are grouped into histor-
ical, personal, psychosocial-environmental,
and clinical factors. Knowledge of these fac-
tors for individual inmates can help correc-
tional health care providers detect and man-
age suicidal risk in this high-risk group (see
Table 1). In addition to these general risk fac-
tors, context-specific factors such as first-term
status or a new HIV infection or hepatitis diag-
nosis should guide health care decisions and
treatment.
Mental Health Services in HIV Primary
Care
In the past, most mental health care was pro-
vided by specialty mental health clinicians. In
the last decade, primary care medical
providers have been thrust into the role of
providing a significant portion of mental health
care. This is partly due to changes in health
care delivery systems, but can also be attrib-
uted to new, safer medications for common
psychiatric disorders and new practice guide-
lines for the treatment of mental health disor-
ders in primary care. Given the prevalence of
psychiatric disorders in patients being treated
for HIV and hepatitis, it is only natural that
mental health care be integrated into general
medical practice.
Screening
Screening for mental health disorders can be
conducted efficiently and cost-effectively.
Both questionnaires that are completed by the
patient and brief screening interviews have
been found to be highly sensitive to the pres-
ence of significant psychiatric symptoms and
impairment.12 Typical screening instruments
for depression in primary care include the
Center for Epidemiological Study Depression
Scale (see HEPP Report, January 2000), the
Hospital Anxiety and Depression Scale
(HADS),13 and other self-report scales of
depression and anxiety. Because it was
developed to take account of the overlap of
psychiatric syndromes and physical symp-
toms, the HADS scale is particularly useful in
primary care and medical specialty clinics.
Screening devices such as these may be less
reliable in correctional populations where
over-reporting of symptoms can hinder accu-
racy. As an alternative, health care providers
can ask a series of questions that are sensi-
tive to the presence of clinically significant
psychiatric symptoms. Brief interviews have
been employed in primary care for the last 10
years. An example is the Prime-MD, which
was developed to diagnose several of the
most common psychiatric disorders seen in
primary care settings. An abbreviated version
of this measure is included as Table 2.
Finally, it should be emphasized that signifi-
cant psychiatric symptoms can be present in
the jail or prison environment without obvious
impairment of an inmate's functioning. Any
effort to screen for psychiatric disorders
should include questions that ask about an
inmate's social functioning and activities such
as attendance at meals, school, job, and
medical appointments.
Alternatives to traditional delivery models
Interest in alternatives to traditional mental
health service delivery models was spurred
by the need to introduce efficient diagnosis
and treatment of common psychiatric disor-
ders into primary care settings. Primary care
settings in the community are important for
several reasons: 1) psychiatric disorders
often present as primarily somatic; 2) primary
care patients with mental health problems are
notoriously high utilizers of medical care; and
3) only a minority of patients with mental
health problems seek help from mental health
specialists.
Physicians and other health care profession-
als can be trained to screen for psychiatric
disorders. Nurses have been used extensive-
ly for this purpose in a variety of settings.
Physicians have received training in medica-
A Primary Care Approach...
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tion algorithms and have been given access
to psychiatrists for consultation. Education of
mental health consumers has been shown to
change patient behavior and can facilitate the
screening and detection process, thus
enhancing the opportunity for treatment of
mental disorders.
Some of the more successful programs have
been termed "collaborative care" models, in
which a mental health professional is integrat-
ed directly into the clinic setting. Often the
clinician has been a psychiatric nurse practi-
tioner or psychologist who acts as an on-the-
scene consultant. Nurse practitioners can
quickly begin patients on medications for a
number of common disorders. Psychologists
are often helpful in situations requiring a dif-
ferential diagnosis. Both these professionals
are adept at brief interventions and crisis situ-
ations.  
At the November 2002 AASLD meeting, a
report from the University of Cincinnati VA
Medical Center discussed the use of a team
of experts in managing HCV therapy for
patients with behavioral, emotional and psy-
chiatric problems.14 Patients were evaluated
for treatment by a multidisciplinary team of
hepatologists, psychiatrists, pharmacists, and
nurses. Sixty-seven percent of those treated
had one or more axis 1 diagnoses, 28% had
an anxiety disorder such as post-traumatic
stress or panic disorder, and 89% had an
addiction disorder.
In spite of this high prevalence of co-morbid
mental illness, 71% of patients completed
treatment. The presenters concluded that by
using a multidisciplinary team approach to
treatment, patients with serious mental/emo-
tional disturbances and chronic HCV can be
treated successfully without undue risk to the
patient. Treatment success based on HCV
RNA clearance was found to be comparable
to that described in the literature for less
impaired patients.
Treatment 
Once the diagnosis has been made, effective
treatment of depression and anxiety are read-
ily available to primary care physicians.
Newer antidepressants that feature more
benign side effect profiles and a larger margin
of safety are available. Algorithms for the use
of antidepressant medications such as those
from the Texas Medication Algorithm Project
(TMAP) provide safe and efficacious treat-
ment in line with practice guidelines from the
American Psychiatric Association and other
professional groups (see  HEPPigram, p. 8). 
Conclusion
Mental disorders are common and can cause
significant impairment among inmates with
chronic illnesses such as HIV and hepatitis C.
Research in the community suggests that
patients with co-morbid chronic viral illness
and mental health problems have poorer
adherence to medical treatment. Additionally,
inmates with chronic illnesses spend more
time incarcerated and may have higher rates
of in-custody rule violations. 
One challenge facing mental health providers
and HIV/hepatitis primary care health care
professionals is how best to diagnose mental
illness and treat these individuals. In the past
decade, changes in the delivery of mental
health care in the free world have spurred
efforts to develop effective interventions and
the technology to deliver efficacious mental
health treatment in non-traditional settings,
such as jails and prisons. Efforts have includ-
ed education for patients and professionals,
inserting mental health professionals into pri-
mary care clinics, the use of brief screening
instruments, and the use of algorithms and
practice guidelines to increase the effective-
ness of psychotropic medications in primary
care settings. Primary care physicians who
care for patients with HIV and/or hepatitis can
now make use of these emerging models and
technologies to better serve inmates suffering
from these and other chronic illnesses.
Disclosures: *Nothing to disclose
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Table 2. The Brief Patient Health Questionnaire
1. Over the last 2 weeks, how often have you been
bothered by any of the following problems?
a. Little interest or pleasure in doing things
b. Feeling down, depressed, or hopeless
c. Trouble falling or staying asleep, or sleeping 
too much
d. Feeling tired or having little energy
e. Poor appetite or overeating
f. Feeling bad about yourself - or that you are a 
failure or have let yourself or your family down
g. Trouble concentrating on things, such as reading 
the newspaper or watching television
h. Moving or speaking so slowly that other people 
could have noticed? Or the opposite - being so 
fidgety or restless that you have been moving 
around a lot more than usual
i. Thoughts that you would be better off dead or of 
hurting yourself in some way
2. Questions about anxiety
a. In the last 4 weeks, have you had an anxiety 
attack – suddenly feeling fear or panic? 
If you checked "NO", go to question #3.
b. Has this ever happened before?
c. Do some of these attacks come suddenly out of 
the blue – that is, in situations where you don't 
expect to be nervous or uncomfortable?
d. Do these attacks bother you a lot or are you 
worried about having another attack?
e. During your last bad anxiety attack, did you have 
symptoms like shortness of breath, sweating, your 
heart racing or pounding, dizziness or faintness, 
tingling or numbness, or nausea or upset stomach?
No               Yes
3. If you checked off any problems on this questionnaire so far, how difficult have
these problems made it for you to do your work, take care of things at home, or get
along with other people?
Not difficult at all       Somewhat difficult       Very difficult       Extremely difficult 
4. Are you taking any medicine for anxiety, depression or stress?        No         Yes
FOR OFFICE CODING: Major Depression Syndrome if answers to #1a or b and five or more of #1a-i are
at least "More than half the days" (count #1i if present at all). Other Depression Syndrome if #1a or b and
two, three, or four of #1a-i are at least "More than half the days" (count #1i if present at all). Panic
Syndrome if all of #2a-e are "YES."
Developed by Drs. Robert L. Spitzer, Janet B.W. Williams, Kurt Kroenke and colleagues, with an educa-
tional grant from Pfizer Inc. 
5
Case study presented by Rick Altice*, M.D., Director, HIV in Prison Program, Yale University AIDS Program. Discussion by Karl Brown**, M.D., Rikers
Island Jail.
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Ask the expert: Case Study – Treatment for HIV and Biopolar Disorder
Discussion
This young woman has a classical presentation for the jail setting in
that she has HIV disease, mental illness, and hepatitis C. She has
also been non-adherent to therapy for both her HIV disease and her
mental illness and is likely not in care. With those biased assump-
tions stated, her HIV and her mental illness are not well controlled
and the jail setting provides a brief opportunity for intervention - hap-
pily, this is done. Her chronic hepatitis C is diagnosed with minimal-
ly elevated liver function tests and work-up for this should be pur-
sued, but her other medical illnesses warrant immediate attention.
Her acute mania is approached with rapid initiation and an increase
of Valproate to therapeutic levels.
Appropriately, she receives PCP prophylaxis with TMP/SMZ daily
and has her late-stage HIV approached with a regimen that has a
high genetic barrier to resistance, due to concerns about non-adher-
ence and the desire to prescribe a somewhat forgiving regimen.
She is observed (I agree with the necessity of observation) to be
adherent to therapy, but is now presenting with symptoms sugges-
tive of Valproate toxicity exemplified by vomiting, dizziness, and nys-
tagmus. Worries regarding immune-reconstituting opportunistic
infections of the CNS are lessened by absence of fever, normal
blood pressure, and no lateralizing signs. 
My approach to this case is, at first, "try not to do any harm."
Importantly, look at the timing of her presentation. What has
changed? The last intervention is likely the one impacting her current
symptomatology, namely the initiation of ddI-EC, tenofovir, and
lopinavir/ritonavir. In and of themselves, the regimen is an excellent
choice, and appropriately dosed for the interaction between ddI and
tenofovir. Kaletra (lopinavir/ritonavir) though, is likely a part of the
problem. It isn't clearly stated that there is an interaction between
ritonavir and Valproate, but the product insert for Valproate states
that "…drugs that are inhibitors of cytochrome P450 enzymes, e.g.
antidepressants, may be expected to have little effect on Valproate
clearance because cytochrome P450 microsomal mediated oxida-
tion is a relatively minor secondary metabolic pathway compared to
glucuronidation and beta-oxidation." 
So now I'm really confused. I know ritonavir is a potent inhibitor of
cytochrome P450, but the package insert ascribes minor problems
for Valproate clearance if this pathway is inhibited. 
The clarity comes when we return to her medical history. She has
hepatitis C. Without liver biopsy or some assessment of liver func-
tion, could it be that her liver glucuronidation and beta-oxidation
pathways are also hindered? Possibly. The short answer is to stop
her Valproate and measure the level. It is also likely that her entire
HAART regimen needs to be held until this is resolved. Checking the
measurable levels should always be done when medications with
narrow therapeutic indices such as VPA are prescribed with riton-
avir-containing medications.
In this case, if the levels are high, several interventions are possible,
from lowering the frequency or dosing of Valproate to changing
Kaletra for a regimen that doesn't contain the most potent P450
inhibitor known. Therein, with the choices available, lies the art of
medicine.
Disclosures:
*Consultant and Speakers Bureau:  Agouron, Abbott, Bristol Myers Squibb,
Boehringer Ingelheim, DuPont, Roche, Glaxo, Gilead, Ortho Biotech, Merck
**Nothing to disclose
A 32-year-old female is admitted to the local jail. She is known to be HIV-infected and to have bipolar disorder. She is manic, paranoid and
refuses to be examined. After a few days of observation in the mental health unit, she agrees to take valproic acid (VPA) 750mg TID. After
one week, she remains paranoid and a nurse finally coaxes her to have her blood drawn. Her VPA level is therapeutic and her HIV work-up
includes the following: CD4 93 (8%), VL = 167,000, VDRL non-reactive, toxoplasma antibody positive, HCV antibody positive, AST/ALT
64/79.
After a few weeks, she remains mildly paranoid, but finally agrees to some medications that might help her. She is started on TMP/SMZ one
double strength tablet po QD for pneumocystis and toxoplasma prophylaxis. Two weeks later, she agrees to start medicines to treat her HIV
and the psychiatric staff are prepared to release her to the general population. There is some concern expressed by nurses that she some-
times refuses her VPA and TMP/SMZ, but in the structured inpatient setting, she eventually accepts them with coaxing. The HIV doctor wants
her to stay in the medical unit for observation and the psychiatrist indicates that there is no psychiatric need for her to remain an inpatient.
An antiretroviral regimen with a high genetic barrier to resistance is selected out of concern for her possible impending non-adherence.  
The patient weighs 165 pounds and is started on ddI-EC (250mg) QD, tenofovir 300 mg QD and lopinavir/ritonavir three capsules  po BID.
She has no GI side effects; however, three days after starting medications, she is brought into the medical unit by staff because she is vom-
iting, dizzy and unable to stand without falling. She is afebrile, normotensive without orthostasis, has a headache and nystagmus bilaterally.  
What would you do and why?
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A Primary Care Approach...
(continued from page 4)
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HEPP Report interview with Eric Avery*, M.D., Assistant Clinical Professor of Psychiatry and Director of HIV Psychiatric Services, University of Texas
Medical Branch, Galveston, Texas
Spotlight: Interview with Eric Avery*, M.D.
Q: Tell us about your work in correctional health care.
A: Until early last year, I worked in the Carol Young Medical Facility,
a minimum security Texas Department of Criminal Justice facility
near Galveston. It's a "step-down" medical facility for several hun-
dred women who come for their medical appointments at the
University of Texas Medical Branch at Galveston (UTMB). A large
number of these women have HIV.
Q: What were some of the most challenging aspects of your work
with inmates?
A: I had to learn how to listen to their stories about their childhood
and adulthood physical, sexual, verbal and emotional abuse. For
many of these women, prison was a retraumatization. Since there
was little I could do to change where they lived, we had to focus on
how they did their time.
Q: What were some of the most common mental disorders that you
encountered in your correctional experience?
A: Substance abuse or dependence, in remission because of incar-
ceration, was epidemic. Major depression was common. I couldn't
believe how often I diagnosed Post-traumatic Stress Disorder
(PTSD) in these women compared to my "free world" work in the HIV
Clinic at UTMB. Sometimes the stories of childhood abuse are such
a problem that patients would tell me them in their first visits. But in
others, to ask questions about childhood abuse instantly puts the
patient in a flashback so I'm really careful. Since in abuse situations
the survivor has felt out of control of what is happening, it's important
for the patient to feel that they control what and how they disclose the
trauma. I often use a childhood abuse questionnaire that I give to the
patient with instructions that they control if and how they complete it.
If they can fill it out, they can bring it to the next session. If they can't
complete it, that's ok too. Then again, perhaps months later after
treatment, we might revisit this traumatic part of their history. 
Q: In your experience, how did these disorders impact upon the abil-
ity of patients to adhere to therapy?
A: Depressed and hopeless patients aren't really motivated to take
on the challenges of HIV treatment. But the Infectious Disease/HIV
physician who worked in the facility had a really good reputation with
these women. That was one of the keys to why these women have
done so well. I worked with this doctor in the HIV Clinic at UTMB so
we both could reinforce what the other was doing.
One of the most crippling aspects of PTSD is the belief that the future
is hopeless, that at any moment another trauma will happen.
Certainly bad stuff can happen in a prison setting and there can be a
lot of bad news if you've got chronic medical disorders like HIV, HCV
and breast cancer. Add these medical problems to a life of trauma
and you have to work really hard to overcome the hopelessness.
Getting these women on an SSRI like Sertraline, and keeping them
on it for a long time helped a lot with the depression, PTSD and med-
ical adherence. For many of these women with HIV who'd been
hopelessly on street drugs and living waiting to die, getting them to
understand they could control their viral loads by what they did with
their medical and psychiatric care - well, it was a transformational
experience for many of them. Watching this was one of the best parts
of my job.
Q: Could you tell us a little about your current situation at the HCV
clinic?
A: In my prison job, I saw many women co-infected with HIV and
HCV but only a few were on treatment for HCV. ALTs were followed
but a lot of women were released before they'd meet criteria for HCV
treatment. In the free world, I've worked for several years in a hepati-
tis clinic. If a patient with HCV has a history of depression or other
psychiatric disorders, I'm consulted to evaluate them before they
begin their treatment with pegylated interferon and ribavirin because
psychiatric disorders can come back with a vengeance while on HCV
treatment.
Q: What kinds of psychiatric problems do you see there?
A: The G.I. physicians have gotten comfortable diagnosing and treat-
ing depression in HCV patients so I am referred more complicated
patients. Like in the prison, these patients have histories of sub-
stance abuse and dependence. Interestingly, many have stopped
years ago and now are facing HCV. Of those still using drugs, ben-
zodiazepine abuse and alcohol are more common than problems
with cocaine. I'm evaluating and treating more and more Bipolar I
and II patients.
What really concerns me is who I'm not seeing in the hepatitis clinic.
I on't see co-infected HIV/HCV patients in this clinic. And I'm not
se ing any patients referred from the psychiatry wards and psychi-
atric clinics. When I do weekend coverage on the inpatient psychi-
atric wards I'm stunned to see how many of these patients now are
HCV-positive. In Houston, investigators at Baylor College of
Medicine discovered that 16.9% of institutionalized psychiatric
patients tested positive for HCV.
Because of the neuropsychiatric side effects of HCV treatment, most
of these patients will not be treated. This is an emerging problem and
the psychiatric profession hasn't figured out that their patients are the
ones disproportionately getting infected with HIV and HCV. My worst-
case scenario is that future psychiatric clinics will have HIV and
hepatitis physicians working in them providing care, instead of the
other way around.
Q: How do you manage patients with depression? What are your
first- and second-line agents? What complications do you watch for?
A: I use all antidepressants in patients with HIV and HCV. Certainly
the first-line agents are the SSRIs. I frequently use Sertraline (Zoloft),
Paroxetine (Paxil) as my first choice for patients with depression and
PTSD. In patients with medical problems the rule is to start low, so
with Sertraline, I start with 25 mg in the morning, and then increase
to 50 mg. You can increase up to 200 mg but I'd be looking up drug-
dr g interactions with the HIV medications as I increased the dose. I
start Paxil with 10 mg but, because it has no metabolites, a non-
adherent patient can get discontinuation symptoms if they suddenly
stop it, so I counsel patients about this. 
Prozac is now generic and cheaper so the prison liked me to use it.
It's a really good antidepressant. Its primary metabolite's half-life is
14 days. In non-adherent patients this can be a benefit. But, if the
patient has bad side effects, they'll last for a long time. It also has
more drug-drug interactions, so I am watching for this when I use it
in HIV-infected patients. 
In patients with liver disease, I'm always careful with how I dose psy-
chiatric medications. Again the rule is go low and increase slowly. But
I tell physicians who treat HIV and HCV not to be afraid to prescribe
antidepressants. Their patients will be more adherent with medical
treatment if they are not depressed. They should become familiar
with a few of them and use them. If they can't improve their patients'
depression, then they should send them on to the psychiatrist.
*Disclosures: Nothing to disclose
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HEPPigram: Texas Medication Algorithm Project (TMAP)
The Depression Algorithms
SSRI = Selective Serotonin Reuptake Inhibitor
BUPSR = Buproprion Sustained Release (WellbutrinSR)
NEF = Nefazodone (Serzone). Note: caution when using nefazodone with
patients receiving protease inhibitors due to inhibition of cyp450 enzyme
system.
VLFXR = Venlafaxine Sustained Release (EffexorXR)
MRT = Mirtazapine (Remeron)
TCA = Tricyclic Antidepressant (Amitriptyline, Nortriptyline)
MAOI = Monoamine Oxidase Inhibitor
ECT = Electroconvulsive Therapy
Stage 1
Stage 2
Stage 3
Stage 4
Stage 5
Stage 6
Stage 7
Any stage(s) can be skipped
depending on the clinical picture.
Strategies for the Treatment of 
Major Depression 
(Nonpsychotic) 
Version 3
Monotherapy
SSRI^^, BUPSR, NEF, VLFXR
or MRT
Monotherapy
SSRI^^, BUPSR, NEF, TCA,
VLFXR or MRT
Lithium Augmentation***
ECT
OTHER
e.g. Lamotrigine, Fluvoxamine
MRT+ BUP, olanzapine, etc.
(Provide Rationale)
Combination Antidepressants:
TCA + SSRI^       BUPSR + SSRI^^
NEF + SSRI^^     BUPSR + NEF
Monotherapy
SSRI^^, BUPSR, NEF, VLFXR,
MRT, MAOI*
From a class other than used in stage 1 or 2
Partial Response
Response
Response
Continuation
Continuation
Continuation
Continuation
Continuation
Continuation
Maintenance
phase when
indicated
*Consider TCA/VLF if not tried
**Lithium, thyroid, buspirone
***Skip if Li augmentation has
already failed
^most studied combination
^^SSRI=Fluox, Sert, Parox, Cital
Response
Response
Response
Response
Response
Response
Partial Response
Partial Response
Partial Response
or Nonresponse
Partial Response
or Nonresponse
Partial Response
or Nonresponse
Partial Response
or Nonresponse
Partial Response
or Nonresponse
Partial Response
or Nonresponse
Partial Response
or Nonresponse
Partial Response
or Nonresponse
Partial Response
or Nonresponse
Stage2A
Augmentation**
Stage 3A
Augmentation**
Stage 1A
Augmentation**
Hepatitis C Management for
Prisoners
January 25-26, 2003
San Antonio, Texas
For abstract forms and more
information, visit
http://www.med.umn.edu/cme/
html/hepcoordinators.html
National Hepatitis
Coordinators' Conference
January 26-30, 2003
San Antonio, Texas
Fee: $125
Call: 800.776.8636
Visit: http://www.med.umn.edu/
cme/brochures2002/hepco-
ord2003/hepcoordbro2003.html
10th Conference on
Retroviruses and 
Opportunistic Infections
February 10-14, 2003
Boston, Massachusetts
call: 703.535.6862
Email: info@retroconference.org
Visit: http://www.retroconfer-
ence.org/2003
Management of HIV/AIDS in the
Correctional Setting
Satellite Videoconference
Hepatitis B & C with HIV Co-
infection: A Diagnostic &
Treatment Update
March 11, 2003
12:30-3:30 p.m. Eastern Time
CME & Nursing Credits Available
www.amc.edu/Patient/HIV/
hivconf.htm
Email: ybarraj@mail.amc.edu
Call: 518.262.4674
15th National HIV/AIDS 
Update Conference
Focusing on the Front Lines:
Practical Lessons in Prevention,
Treatment, and Care
March 30-April 2, 2003
Miami, Florida
Scholarships available
Email: nauc@total.net
Visit: http://www.amfar.org/nauc
Clinical Updates in
Correctional Health Care
NCCHC Spring Meeting
April 12-15, 2003
Anaheim, California
Call: 773.880.1460
Visit: http://www.ncchc.org
Save the 
Dates
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HIV
FDA Approves Once-Daily Version of Zerit
The FDA approved a new "extended release"
version of Bristol-Myers Squibb's Zerit (d4T,
stavudine). The new formulation, which will be
marketed as Zerit XR, has been shown to main-
tain measurable plasma concentrations in
patients for 24 hours following the once-a-day
dose. Zerit XR is indicated for treatment of HIV
infection in combination with other antiretrovirals.
The full label will be available in the future at
http://www.fda.gov/cder/approval/index.htm. As
of January 10, 2003, Zerit XR was not yet avail-
able in pharmacies. Kaiser Daily HIV/AIDS
Report, 1/02/03
Report: Infection by Closely-Related HIV
Strains Possible
A recent issue of Naturereports findings from
Bruce Walker, M.D., a researcher at
Massachusetts General Hospital and Harvard
Medical School, of an individual infected with two
closely related strains of HIV. The two strains dif-
fered in overall amino acid sequence by about 12
percent (variation between subtypes of HIV is
about 30 percent) and is the first published report
of infection by two strains of the same subtype.
This data provides further strength to the recom-
mendation that HIV-infected individuals protect
themselves from super-infection with other HIV
strains. NIH News Release, 11/27/02
Gilead to Buy Triangle Pharmaceuticals
California-based Gilead Sciences has agreed to
buy North Carolina-based Triangle Pharma-ceuti-
cals for $464 million. With the deal, Gilead's
development portfolio is strengthened with three
of Triangle's HIV and HBV drugs, including
Coviracil (FTC, emtricitabine), which could be
approved by the FDA in 2003. According to
Gilead's chief operating officer, Coviracil (an
NRTI) could be combined with Gilead's Viread to
make a once-a-day tablet.
Kaiser Daily HIV/AIDS Report, 12/06/02
Study to Evaluate Tenofovir as Prevention
Method
The Bill & Melinda Gates foundation awarded a
$6.5 million, three-year grant for a multinational
clinical trial to evaluate Gilead Science's tenofovir
(Viread) as an approach to HIV prevention. The
trial is designed to evaluate the safety and effica-
cy of tenofovir as a method of reducing the risk of
HIV infection in sexually active adults who are
regularly exposed to the virus. 
GileadPress Release, 10/28/02
HIV-Positive Alabama Inmates Sue Over
Living Conditions
A suit filed on behalf of five HIV-positive inmates
at Alabama's Limestone Correctional Facility
charges the state Department of Corrections and
NaphCare with "inadequate living conditions" and
medical care. According to the plaintiffs' lawyer,
more than 40 inmates with HIV have died at the
Limestone facility over the past three years.
Limestone is a special unit of the state prison sys-
tem and houses more than 200 HIV-positive
inmates. Kaiser Daily HIV/AIDS Report, 11/25/02
HCV
FDA Approves Pegasys/Copegus
Combination for HCV Treatment
The FDA approved combination therapy with
Roche Pharmaceutical's Pegasys and Copegus
(ribavirin) for the treatment of adults with chronic
HCV infection who have compensated liver dis-
ease, and have not been treated with interferon
alpha. Pegasys, a premixed solution, is injected
once a week; Copegus is available as a 200mg
tablet (administered at 800 to 1200mg) taken
twice daily as a split dose. Kaiser Daily HIV/AIDS
Report, 12/05/02
HCV Therapy-Related Depression Reduces
Adherence, Decreases Viral Response
A study presented at AASLD examined whether
the degree of depression caused by HCV thera-
py was related to the type of therapy (either
INF/ribavirin or PEG-INF/ribavirin compared to
INF monotherapy). Results showed that combi-
nation therapy significantly increased the depres-
sion induced by therapy, and as adherence is
affected by severe depression, it often results in
early dropout, resulting in poor viral response.
The study suggests that better control of depres-
sion at the initiation of therapy might improve
compliance, and ultimately, viral response.
www.hivandhepatitis.com, 11/18/02
Inside News
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Resources & Websites
Office of HIV Psychiatry
American Psychiatric Association
Training and education, technical assistance,
policy guidance, and resources.
Phone: 202-682-6163
email: aids@psych.org  web:
http://www.psych.org/aids/
National Institute of Mental Health Office of
AIDS Research
Phone: 301-443-6100
email: nimhaids@ngmsmtp.nimh.nih.gov
web: http://www.nimh.nih.gov/oa/
Criminal Justice/Mental Health Consensus
Project
http://consensusproject.org/
Medscape: HIV/AIDS
http://www.medscape.com/hiv-aidshome
AIDSinfo
A service of the U.S. Department of Health and
Human Services. AIDSinfo is a merger of the
HIV/AIDS Clinical Trials Information Service
(ACTIS) and its sister service, the HIV/AIDS
Treatment Information Service (ATIS)
http://www.aidsinfo.nih.gov/
Self-Assessment Test for Continuing Medical Education Credit
Brown Medical School designates this educational activity for 1 hour in category 1 credit toward the AMA Physician’s Recognition Award.
To be eligible for CME credit, answer the questions below by circling the letter next to the correct answer to each of the questions. 
A minimum of 70% of the questions must be answered correctly. This activity is eligible for CME credit through July 31, 2003. 
The estimated time for completion of this activity is one hour and there is no fee for participation.
1. Which of the following is a "protective" factor that may
decrease the likelihood of suicidal thinking and behavior?
a) Married or in a significant relationship
b) Having children under the age of 18
c) Involved in mental health treatment
d) All of the above
e) None of the above
2. Brief screening interviews and self-report scales have been
found to be sensitive to the presence of significant psychiatric
symptoms and impairment and may be useful in correctional 
settings. 
a) True
b) False
3. According to the Bureau of Justice, the following number of
state prisoners were receiving psychotherapy or counseling in
the year 2000:
a) 3%
b) 13%
c) 27%
d) 41%
4. Which of the following might be a sign of depression?
a) Trouble falling or staying asleep, or sleeping too much
b) Feeling tired or having little energy
c) Poor appetite or overeating
d) Trouble concentrating on things, such as reading the 
newspaper or watching television
e) All of the above
5. The presence of major mental illness is an absolute contraindi-
cation to treatment for hepatitis C infection.
a) True
b) False
6. In the absence of cirrhosis, patients with chronic viral hepatitis
are unlikely to demonstrate any cognitive impairment when 
studied with neuropsychological testing.
a) True
b) False
BROWN MEDICAL SCHOOL •  OFFICE OF CONTINUING MEDICAL EDUCATION •  BOX G-A2  •  PROVIDENCE, RI 02912
The Brown Medical School is accredited by the Accreditation Council for Continuing Medical Education (ACCME)to provide continuing medical 
education activities for physicians.  
The use of the Brown Medical School name implies review of the educational format and material only.  The opinions, recommendations 
and editorial positions expressed by those whose input is included in this bulletin are their own.  They do not represent or speak for the 
Brown Medical School.
For Continuing Medical Education credit please complete the following and mail or fax to 401.863.2660 or 
register online at www.hivcorrections.org. Be sure to print clearly so that we have the correct information for you.
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HEPP Report Evaluation
5 Excellent    4 Very Good    3 Fair    2 Poor    1 Very Poor
1. Please evaluate the following sections with respect to:
educational value clarity
Main Article 5  4  3  2  1   5  4  3  2  1     
HEPPigram 5  4  3  2  1   5  4  3  2  1  
Inside News 5  4  3  2  1   5  4  3  2  1
Save the 
Dates 5  4  3  2  1   5  4  3  2  1
2. Do you feel that HEPP Report helps you in your work?
Why or why not?
3. What future topics should HEPP Report address?
4. How can HEPPReport be made more useful to you?
5. Do you have specific comments on this issue?
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